Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported Phase I and Phase I/II results from three studies evaluating the safety, tolerability and dosing of MLN9708, the first oral proteasome inhibitor in clinical trials. The studies evaluated once or twice weekly oral dosing of MLN9708, alone or in combination, in patients with relapsed and/or refractory or previously untreated multiple myeloma (MM). These data were announced during a series of oral presentations at the 53rd annual meeting of the American Society of Hematology (ASH), held December 10th – 13th in San Diego, California.
“These data reveal a promising profile for this therapy and clearly support further investigation of MLN9708 in patients with multiple myeloma, including as a single agent in heavily pre-treated patients as well as in combination therapy for those who have received no prior treatment for their disease,” said Karen Ferrante, M.D., Chief Medical Officer, Millennium.
Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study (Abstract #301)
The primary objectives of this study were to determine the safety, tolerability and maximum tolerated dose (MTD) of oral MLN9708 in patients with relapsed and/or refractory MM. To date, 36 of the 56 patients in the study have been enrolled to expansion cohorts. Results, which were presented by Paul G. Richardson, M.D., Dana-Farber Cancer Institute, showed:
Patients with measurable disease and no grade =2 peripheral neuropathy were eligible. For the dose escalation phase patients required two or more prior therapies, which must have included bortezomib, thalidomide or lenalidomide, and corticosteroids. At MTD patients were enrolled to four expansion cohorts: relapsed and refractory, bortezomib-relapsed, proteasome inhibitor-naïve, and prior carfilzomib exposure. MLN9708 was administered orally on a twice-weekly basis in 21 day cycles.
Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study (Abstract #816)
This study evaluated MLN9708 in 32 patients who had received two or more prior therapies. The primary objectives of this ongoing study were to determine the safety, tolerability and MTD of weekly MLN9708. Results presented by Shaji K. Kumar, M.D., showed:
Patients with MM who had received =2 prior therapies, which must have included bortezomib, thalidomide or lenalidomide, and corticosteroids, and no grade =2 peripheral neuropathy were eligible. MLN9708 was orally administered weekly on a 28 day cycle. Dose escalation proceeded from 0.24 mg/m2 following a 3+3 scheme based on the occurrence of DLTs in cycle 1.
Phase 1/2 Dose-Escalation Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (Abstract #479)
This study evaluated MLN9708 in 15 patients with previously untreated multiple myeloma. The primary objectives of this ongoing study were to determine the safety, tolerability, MTD and recommended Phase II dose, of weekly MLN9708 in combination with lenalidomide and dexamethasone. Results presented by Jesus G. Berdeja, M.D., Sarah Cannon Research Institute, showed:
Patients with previously untreated MM, an ECOG score of 0-2 and adequate hepatic, renal and hematological function and no grade =2 peripheral neuropathy were eligible. Patients received oral MLN9708 weekly, lenalidomide 25 mg on days 1-21, and dexamethasone 40 mg weekly, for up to twelve 28-day cycles. Dose escalation of MLN9708 proceeded from 1.68 mg/m2 following a 3+3 scheme based on the occurrence of DLTs in cycle 1.
Editor’s Note: This press release is also available under the Media section of the Company’s website at: www.millennium.com/InTheNews.aspx.
Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company’s research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50102740&lang=enBusiness Wire
Last updated on: 13/12/2011
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.